Legal Representation
Attorney
Christopher D. Olszyk, Jr.
USPTO Deadlines
Next Deadline
1466 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-07-18)
Due Date
July 18, 2029
Grace Period Ends
January 18, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
22 events| Date | Code | Type | Description |
|---|---|---|---|
| Jul 18, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Jul 18, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| May 2, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION |
| May 2, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Apr 12, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Mar 30, 2023 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Mar 15, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Mar 13, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Mar 13, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Dec 30, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Dec 30, 2022 | GNRT | O | NON-FINAL ACTION E-MAILED |
| Dec 30, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Dec 7, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Dec 6, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Dec 6, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jul 6, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jul 6, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Jul 6, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Jun 28, 2022 | DOCK | D | ASSIGNED TO EXAMINER |
| Feb 17, 2022 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Feb 16, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Feb 15, 2022 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 010
Biopsy tests and devices, namely, medical instruments for use in performing biopsies and medical diagnostic apparatus for testing biomarkers; Biopsy tests and devices, namely, medical instruments for use in performing biopsies and medical diagnostic apparatus for evaluating appropriate immunotherapy cancer treatments; Cancer screening tests and devices, namely, medical devices for detecting risk factors and probability of cancer reoccurrence; Cancer screening tests and devices, namely, medical devices for evaluating immunotherapy cancer treatment options; Cancer screening tests and devices, namely, medical devices for matching cancer diagnosis with cancer treatments; Medical testing device for diagnosing cancer and detecting biological traits that effect the risk of reoccurrence; Medical diagnostic apparatus for testing a patient's response to various immunotherapy cancer treatment options in order to help determine the most effective course of treatment for that patient; Blood testing apparatus for cancer diagnosis and evaluation of treatment options; Medical testing devices for tumor diagnosis and treatment evaluation
First Use Anywhere:
20211200
First Use in Commerce:
20211200
Additional Information
Design Mark
The mark consists of the block letter wording DETERMA in blue, stacked over three leaf shape designs being squares having rounded corners at the top left and bottom right of each, and wherein the first is green with the letters "Rx" appearing in white in the center, the second is blue with the letters "IO" appearing in white in the center, and the third is red with the letters "Tx" appearing in white in the center.
Color Claim
The color(s) blue, green, red, and white is/are claimed as a feature of the mark.
Classification
International Classes
010
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"RX", "IO", AND "TX"
USPTO Documents
Loading USPTO documents...